Powder: -20°C for 3 years | In solvent: -80°C for 1 year
FT-1518 ,exhibits antitumor activity, is a new generation selective, potent and oral bioavailable mTORC1 and mTORC2 inhibitor.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
25 mg | 6-8 weeks | $ 1,330.00 | |
50 mg | 6-8 weeks | $ 1,740.00 | |
100 mg | 6-8 weeks | $ 2,500.00 |
Description | FT-1518 ,exhibits antitumor activity, is a new generation selective, potent and oral bioavailable mTORC1 and mTORC2 inhibitor. |
In vitro | FT-1518 is a novel, selective, potent, and orally bioavailable inhibitor targeting both mTORC1 and mTORC2 pathways, demonstrated by its potent inhibition of key biomarkers (mTORC1 & 2 biomarkers [pAkt(S473) and pS6(S240/244) or p70 S6K]), without affecting the PI3K biomarker [pAkt(T308)]. This compound exhibits pronounced antitumor properties and has shown significant growth inhibitory effects across a wide array of hematologic and solid tumor cell lines, with the majority of its activities observed in the low nanomolar range. |
In vivo | FT-1518 demonstrates a dose-dependent increase in tumor growth inhibition (TGI) across a range of solid tumor xenografts, with more significant effects observed at higher doses. |
Molecular Weight | 394.47 |
Formula | C20H26N8O |
CAS No. | 1313026-58-2 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
FT-1518 1313026-58-2 PI3K/Akt/mTOR signaling mTOR FT 1518 FT1518 inhibitor inhibit